Tether, the stablecoin behemoth, is expanding its investments and operations into a new field: biotech. The company recently disclosed it acquired a majority stake in Blackrock Neurotech, a company that specializes in producing Brain-Computer-Interfaces (BCIs) to help people experiencing loss of neurological functions.

Tether’s investment of $200 million in Blackrock Neurotech will allow the company to roll out part of its products to the wider market and provide the funds necessary to power Blackrock Neurotech’s research and development processes. The investment marks the launch of Evo, another of Tether’s business divisions, that will support initiatives combining humans and tech to advance humanity’s possibilities.

The solutions pioneered by Utah-based Blackrock Neurotech have already made headlines. In 2016, a paralyzed patient using a robotic arm fist-bumped former President Obama, being able to “feel” this interaction via a neurological interface.

Paolo Ardoino, CEO of Tether, remarked on the relevance of Tether’s investment in Blackrock Neurotech. He stated:

Blackrock Neurotech is just the beginning of our journey through Tether Evo to venture into projects that redefine the boundaries of what’s possible at the intersection of technological innovation and human potential.

Furthermore, Ardoino assessed that Blackrock Neurotech represented a future “where technology not only complements but enhances our human experience.” Florian Solzbacher, co-founder of Blackrock Neurotech, explained that, due to Tether’s tech focus, the company “couldn’t dream of a better partner than Tether to bring our shared vision to life.”

Before, the company had announced a full reorganization of its Business structure, announcing the launch of four different divisions: Tether Finance, Tether Data, Tether Power, and Tether Edu.

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。